Ozempic explained on TikTok: what a pulmonologist gets right and wrong

What did @your_pulmonologist actually say?

Honestly? It's hard to say. The transcript from this 112K-view video is almost entirely unintelligible. Fragments like "when the body moves on the left, he takes a glp" and "Leto greatly bazan kam hona shirouan" do not constitute a medical explanation. Whatever was actually said on camera did not survive the transcription process in any usable form.

The caption promises that "Dr Muhammad Ahmad explains the science, safety, and medical reality" behind Ozempic. That's a significant promise. GLP-1 receptor agonists are among the most consequential drug classes of the past decade, and 112,700 people watched this video expecting real information. Based on the transcript provided, it is not possible to verify a single specific claim about semaglutide's mechanism, dosing, safety profile, or clinical evidence. The transcript appears to be either a failed auto-translation from Urdu or a badly garbled audio capture. Either way, the content as recorded is not fact-checkable in any conventional sense.

Does the science back this up?

There is no coherent claim in the transcript to test against the science. That said, here is what the actual peer-reviewed literature says about Ozempic (semaglutide), since that is what viewers came for.

Semaglutide is a GLP-1 receptor agonist originally approved by the FDA for type 2 diabetes management (Ozempic, 2017) and later at higher doses for chronic weight management (Wegovy, 2021). It works by mimicking glucagon-like peptide-1, a gut-derived hormone that stimulates insulin secretion in a glucose-dependent manner, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a mean body weight reduction of 14.9% over 68 weeks in adults without diabetes. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) found a 20% reduction in major cardiovascular events in overweight or obese adults with established cardiovascular disease. These are real, replicated findings from large randomized controlled trials.

What did they get wrong (or right)?

It is genuinely impossible to score this video's specific claims because no specific claims survived the transcript. That is itself a problem worth naming plainly. A pulmonologist posting under the handle @your_pulmonologist, making educational content about a drug their specialty does not primarily manage, is already operating at the edge of their clinical lane. Obesity medicine and endocrinology are the fields where GLP-1 expertise lives.

The hashtags tell a different story than the caption. Tags like "fatlossexcercise" and "gymdiet" place this video in weight-loss influencer territory, not clinical education. That framing matters because it shapes what viewers expect and what they might do with the information. If the video recommended Ozempic as a general weight-loss tool without discussing contraindications (personal or family history of medullary thyroid carcinoma, pancreatitis risk, or the need for medical supervision), that would be a meaningful omission. We cannot confirm or deny that based on what was provided.

No credit can be given for accuracy here. No penalty either. The transcript simply does not support a verdict.

What should you actually know?

If you watched this video hoping to understand how Ozempic works, here is a grounded summary based on published evidence, not this transcript.

• Semaglutide is not a weight-loss shortcut. It is a prescription medication with a specific mechanism, real side effects (nausea, vomiting, delayed gastric emptying, rare but serious pancreatitis risk), and it requires ongoing medical supervision.
• The weight loss seen in trials largely reverses after stopping the drug. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found participants regained two-thirds of their lost weight within one year of discontinuation.
• Compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. The FDA has issued multiple warnings about compounded versions, including those sold through telehealth platforms, citing quality and dosing concerns.
• GLP-1 drugs do not "burn fat" in the simple sense weight-loss content often implies. The weight reduction is driven primarily by reduced caloric intake due to appetite suppression, not direct fat metabolism.
• Anyone considering semaglutide should speak with a licensed prescriber who can review their full medical history, not a TikTok video with 112K views and an incoherent transcript.